AtriCure announced the first patient treatment with its AtriClip FLEX-Mini device for left atrial appendage (LAA) management.

The device, which recently received 510(k) clearance from the US Food and Drug Administration (FDA), is claimed to be the smallest profile surgical LAA device in the market.

The AtriClip FLEX-Mini device is designed to provide surgeons with enhanced access and increased visibility during procedures.

This device builds upon the proven technology of the AtriClip platform, which is known for its ease of use and design simplicity.

AtriCure CEO and president Michael Carrel said: “The AtriClip FLEX-Mini is an unparalleled product that reinforces our position as the market leader in surgical LAA management.

“With nearly 600,000 AtriClip devices sold globally, we are having a significant impact on patients’ lives. Continuing to innovate and enhance the unique features of our AtriClip platform will support even greater growth in this market.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The AtriClip FLEX-Mini device features a fully enclosed design with parallel beams that apply constant closing force, thereby ensuring optimal pressure on the atrial tissue.

Its low-profile design does not compromise stability, allowing for better control during surgeries. The ergonomic handle of the device is designed for single-handed placement, making the application process more straightforward for physicians.

In April 2024, AtriCure launched the cryoSPHERE+ cryoablation probe device to improve post-operative pain management.

The cryoSPHERE+ probe, which is part of the cryoICE platform, features advanced insulation technology that reduces freeze times by 25% compared to the legacy cryoSPHERE device.